Barcelona
 
Home
Welcome Note
Faculty List
Committees
Timetable
Scientific Program
Satellite Symposia
Thursday
Friday
Saturday
Sunday
Abstracts
Abstract Submission
Best Abstract Awards
Sponsorship & Exhibition
Sponsors
Exhibitors
CME
Registration
Invitation Letter
Accommodation
Poster Presentation
Poster List
Abstracts List
Poster Presentation Guidelines
General Information
Before you Travel
Things to Do
Italian Agent
Previous and upcoming CODHy Congresses
Partners
Links
Contact Us

  Scientific Program Print

Hall A
 
Session 11
08:30-10:00
Type 2 Diabetes- Therapeutic Quandaries I
Chairs: A. Ametov, Russia & K. Petersen, USA

Supported by an unrestricted educational grant from Sanofi

08:30-08:35 Introduction


 
08:35-08:55
08:55-09:15
09:15-09:35
Should we begin by replacing insulin deficiency or reducing insulin resistance?
Early insulin replacement therapy: A. Karasik, Israel
Reducing insulin resistance: G. Shulman, USA
Discussion
09:35-09:55
 
 
09:55-10:00
Early insulinization to prevent diabetes progression
I. Raz, Israel
 
Discussion

10:00-10:30
Coffee Break

Session 12
10:30-12:00
News on the Incretins
Chairs: B. Itzhak, Israel & F. Giorgino, Italy
Supported by an unrestricted grant from Boehringer Ingelheim / Eli Lilly
10:30-10:35 Introduction
10:35-10:55
New insights on the mechanisms of action of DPP-4 inhibitors
M. Nauck, Germany
10:55-11:15
A review of the cardiac and endothelial effects of incretin therapies
F. Giorgino, Italy
11:15-11:35
 
 
11:35-12:00
The pancreatic islet incretin system
M. Donath, Switzerland
 
Discussion

12:00-13:00
Lunch Break

Session 13
13:00-15:00
Insulin Pump for T2D
Chair: O. Mosenzon, Israel
Supported by an unrestricted educational grant from Medtronic
13:00-13:05
Introduction
 
 
13:05-13:25
 
13:25-13:45
 
13:45-14:05
Insulin pump for T2DM:
The use of CSII in T2DM
Y. Reznik, France
The misuse of CSII in T2DM
O. Cohen, Israel
Discussion on current indications and future trends
14:05-14:25
 
Insulin analogues
A. Garber, USA
 
 
14:25-14:40
14:40-14:55
14:55-15:00
Intensification of insulin therapy in primary care:
Which is preferable - Basal Bolus or Premix?
Basal Bolus: H. Yki-Jarvinen, Finland
Premix: O. Mosenzon, Israel
Discussion
 
15:00-15:30
Coffee Break
 
Session 14
15:30-17:00
Clinical Development of Glucose-Lowering Medications: Global and Regional
Chair: B. Hirshberg, USA & C. Bailey, UK
15:30-15:35
Introduction
15:35-15:55
What type of data will we get from these large outcome studies?
C. Bailey, UK
15:55-16:15
Potential implications for clinical practice
S. Del Prato, Italy
16:15-16:35
A cardiologist in the endocrine world
C. Lotan, Israel
16:35-16:55
 
 
16:55-17:00
Industry perspective
B. Hirshberg, USA
 
Discussion
Hall B
 
Session 15
08:30-10:00
New Treatment Strategies
Chairs: M. Shestakova, Russia& J. Davidson, USA
08:30-08:35
Introduction
 
 
08:35-08:50
08:50--09:05
09:05-09:15
How low should blood glucose control be?
Very low: P. Pozzilli, Italy
Not too low: E. Bonora, Italy
Discussion
 
 
09:15-09:30
09:30-09:45
09:45-10:00
Individualization therapy: Fashion or fact?
Fashion: C.J. Tack, Netherlands
Fact: J. Davidson, USA
Discussion

10:00-10:30
Coffee Break

Session 16
10:30-12:00
The Unsolved Problem of Hypoglycaemia
Chairs: G. Jermendy, Hungary & S. Heller, UK
10:30-10:35
Introduction
 
 
10:35-10:50
10:50-11:05
11:05-11:20
Hypoglycaemia is of similar importance for every patient
Yes:
S. Heller, UK
No: M. Theodorakis, Greece
Discussion
 
 
11:20-11:35
11:35-11:50
11:50-12:00
Hypoglycaemia is of cardiovascular importance
Yes: N. Lalic, Serbia
No: I. Tkáč, Slovakia
Discussion

12:00-13:00
Lunch Break

Session 17
13:00-15:00
Hypertension
Chairs: Y. Yodfat, Israel & D. de Zeeuw, The Netherlands
13:00-13:05
Discussion
 

13:05-13:20
13:20-13:35

Should we treat proteinuria with more than one RAAS inhibitor?

Pro: M. Ravid, Israel
Con: D. de Zeeuw, The Netherlands
 
13:35-13:55
Should albuminuria be a target of treatment in hypertension?
H. Haller, Denmark
13:55-14:15
Reno-protection vs. cardio-protection: A clinical dilemma
M. Ravid, Israel
14:15-14:35
 
14:35-15:00
New opportunities for kidney protection in diabetes
A. Solini, Italy
Discussion
 
15:00-15:30
Coffee Break
 
Session 18
15:30-17:00
Lifestyle Therapies for Diabetes
Chair: M. Laakso, Finland & W. Cefalu, USA
15:30-15:35
Introduction

15:35-16:05
Combination of GLP1 and insulin as first-line therapy
J. Vora, UK
16:05-16:45
 
 
16:45-17:00
Prevention of diabetes: From research to practice
W. Cefalu, USA
 
Discussion: Diabetes Prevention
Hall C
 
Session 19
08:30-10:00
Pathophysiology of Type 2 Diabetes
Chairs: I. Tkac, Slovakia and P. Pozzilli, Italy
08:30-08:35
Introduction


08:35-08:50
08:50-09:05
09:05-09:15
Impaired insulin secretion in T2D
It's all beta cell mass: J. Meier, Germany
It's all beta cell function: R. Bonadonna, Italy
Discussion
 
 
09:15-09:30
09:30-09:45
09:45-10:00
Genetic screening for the risk of diabetes: Valuable or worthless?
Valuable: M. Laakso, Finland
Worthless: V. Lyssenko, Sweden
Discussion

10:00-10:30
Coffee Break

Session 20
10:30-12:00
Learning From the Literature
Chair: N. Katsilambros, Greece & E. Mannucci, Italy
10:30-10:35
Discussion
 
10:35-10:55
 
10:55-11:05
Meta-analysis in diabetes: Both a salvation and a danger
P. Home, UK
Discussion
 

 
11:05-11:25
11:25-11:45
11:45-12:00
Is glucose control important for prevention of cardiovascular disease in diabetes?
Yes: P. Pozzilli, Italy
No: E. Mannucci, Italy
Discussion
 
12:00-13:00
Lunch Break

Session 21
13:00-15:00
The Place of PPAR Gama Therapy in T2D
Chair: R.A. DeFronzo
Supported by an unrestricted educational grant from Takeda Pharmaceuticals International, Inc.
13:00-13:05
Introduction
13:05-13:35
The liver as a therapeutic target for type 2 diabetes
G. Shulman, USA
13:35-14:05
In vivo actions of PPARs: Glycemic control, insulin sensitivity, insulin secretion
R.A. DeFronzo, USA
14:05-14:35
 
 
 14:35-15:00
Thiazolidinediones: Cardiovascular benefits far outweigh the risks
G. Schernthaner, Austria
 
Discussion
 
15:00-15:30
Coffee Break
 
Session 22
15:30-17:00
Future Therapy for Diabetes
Chair: I. Raz, Israel
Supported by an unrestricted educational grant from Takeda Pharmaceuticals International, Inc. 
15:30-15:35
Introduction
15:35-16:15
GPR40 and TAK875
Clinical/Basic science
 C. Burant, USA
16:15-16:45
 
 
 
16:45-17:00
11-beta hydroxysteriod dehydrogenase: a therapeutic target for diabetes management?
A. Scheen, Belgium
 
Discussion


Home    Sponsors    Regesteration    Contact Us   
 
Copyright © 2007 comtecmed.com. All rights reserved.   The website was last updated on 16/01/2014 Created by     WebStudio.co.il